Newly published study shows that Voraxaze® can improve clinical outcomes in patients with high-dose methotrexate induced acute kidney injury

Philadelphia, PA – 13 January 2024: SERB Pharmaceuticals (SERB) announces the publication of the largest and most comprehensive study to date of patients with high-dose methotrexate (MTX)- induced acute kidney injury (MTX-AKI) treated with and without Voraxaze® (glucarpidase).Researchers from Mass General Brigham and Harvard Medical School (Boston, MA) analyzed data from more than 700 adult patients with MTX-AKI across 28 major U.S. cancer centersi and found that patients who received Voraxaze® had significantly higher odds of kidney recovery as well as faster time to kidney recovery compared to those who did not receive Voraxaze®.iiResults were published online ahead of print on 06 January 2025 in the peer-reviewed journal Blood, the flagship journal of the American Society of Hematology.The data showed that: • Treatment with Voraxaze® was associated with a 2.70-fold higher adjusted odds of kidney recovery at hospital discharge (95% CI, 1.69–4.31) compared to those not treated with Voraxaze®. • Patients treated with Voraxaze® had faster time-to-kidney recovery (adjusted hazard ratio [aHR], 1.88, 95% CI, 1.18–3.33)• Treatment with Voraxaze® was associated with a lower likelihood of grade ≥ 2 neutropenia (adjusted odds ratio [aOR] 0.50 [95% CI, 0.28–0.91]) and grade ≥ 2 transaminitis at day 7 (aOR 0.31 [95% CI, 0.13–0.77]).“The publication offers physicians additional evidence to support the appropriate use of Voraxaze® to treat patients with this severe and potentially life-threatening toxicity,” said Dr. Suzanne Ward, Sr. Director of Scientific Affairs at SERB. A previous analysis of the data was shared on 9 December 2023 in an oral presentation at the American Society of Hematology meeting in San Diego, CA.iiiFor the full press release from Mass General Brigham, please click here.About SERB PharmaceuticalsSERB is a global specialty pharmaceutical company with a growing portfolio of medicines for emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families. SERB is a leading provider of essential acute care medicines, addressing unmet medical needs and supplying antidotes and medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. Learn more at SERB.com.For further information contact:SERB Pharmaceuticals: Chris Sampson, Corporate Communications [email protected]; Tel: +44 (0)7773 251 178About Voraxaze® (glucarpidase)iv:Indication and Limitations of UseVoraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal functionLimitations of Use: Voraxaze® is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexateImportant Safety InformationWarnings and PrecautionsSerious Hypersensitivity ReactionsSerious hypersensitivity reactions, including anaphylactic reactions, may occur. Serious hypersensitivity reactions occurred in less than 1% of patientsMonitoring Methotrexate Concentration/Interference with AssayMethotrexate concentrations within 48 hours following Voraxaze® administration can only be reliably measured by a chromatographic method due to interference from metabolites. Measurement of methotrexate concentrations within 48 hours of Voraxaze® administration using immunoassays results in an overestimation of the methotrexate concentrationADVERSE REACTIONSIn clinical trials, the most common related adverse events (occurring in >1% of patients) were paresthesia, flushing, nausea and/or vomiting, hypotension and headacheDRUG INTERACTIONSVoraxaze® can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended, and may also reduce the concentrations other folate analogs or folate analog metabolic inhibitorsPlease see Full Prescribing Information.REFERENCES:I Cancer Centers included: Brigham and Women’s Hospital, Boston, MA; Duke Cancer Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Massachusetts General Hospital, Boston, MA: Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; Memorial Sloan Kettering, New York, NY; Moffitt Cancer Center, Tampa, FL; Oschner Health System, New Orleans, LA; Ohio State University Comprehensive Cancer Care Center, Columbus, OH; Stanford Cancer Institute, Stanford, CA; Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, PA; University of Alabama Birmingham Hospital, Birmingham, AL; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Florida Cancer Center, Gainesville, FL; University Hospitals Cleveland Medical Center, Cleveland, OH; University of Kentucky, Louisville, KY; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; Hospital of the University of Pennsylvania, Philadelphia, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Virginia Hospital, Charlottesville, VA; Vanderbilt University Medical Center, Nashville, TN; Washington University in St. Louis, St. Louis, MO; Yale New Haven Hospital, New Haven, CTii Gupta S et al. “Glucarpidase for Treatment of High-Dose Methotrexate Toxicity” Blood DOI: 10.1182/blood.2024026211.iii Gupta S, LaCasce A, Leaf RK, Kaunfer S, Leaf DE. Clinical Outcomes in Patients with High Dose Methotrexate Toxicity Treated with Vs. without Glucarpidase [abstract 268]. In: 65th Annual American Society of Hematology Annual Meeting and Exposition; December 9-12 2023; San Diego, CA (https://ash.confex.com/ash/2023/webprogram/Paper189432.html, accessed November 10, 2023).iv Voraxaze®. Prescribing information. BTG International Inc.; 2019.Back to news Related news: SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million SERB Pharmaceuticals Announces ThyroSafe 130mg Potassium Iodide Tablets are Now Commercially Available in the US Search Legal notice Privacy policies Cookie Settings Modern Slavery Code of Conduct Accreditations Accessibility Contact us This website is intended for a global audience. This website may contain information on worldwide products and services, not all of which are available in every location. A reference to a product or service on this website does not imply that such product or service is or will be available in your location. The products referred to on this website may be subject to different regulatory requirements depending on the country. © 2026 SERB. All rights reserved. SERB® and the SERB logo are registered trademarks of SERB S.à.r.l.. BTG® is a registered trademarks of Protherics Medicines Development Ltd. Veriton© is a registered trademark of Veriton Pharma Limited. All other products mentioned are trademarks of their respective owners. You are leaving the SERB.com global corporate website This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website. Cancel Leave Choose your region RegionGlobalUSFranceBelgium Accept Cancel

The release as fetched from its publisher. serb.com ↗